Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume -, Issue -, Pages 106002802096445
Publisher
SAGE Publications
Online
2020-10-15
DOI
10.1177/1060028020964451
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
- (2020) Giacomo Sgalla et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Luca Richeldi et al. Lancet Respiratory Medicine
- Idiopathic pulmonary fibrosis
- (2017) Luca Richeldi et al. LANCET
- Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
- (2017) Kelly Fleetwood et al. Journal of Managed Care & Specialty Pharmacy
- Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
- (2016) Bram Rochwerg et al. BMC Medicine
- Drug Treatment of Idiopathic Pulmonary Fibrosis
- (2016) William J. Canestaro et al. CHEST
- FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis
- (2016) Ganesh Raghu et al. EUROPEAN RESPIRATORY JOURNAL
- Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis
- (2016) Paola Rogliani et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
- (2015) Ganesh Raghu et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
- (2015) John Hutchinson et al. EUROPEAN RESPIRATORY JOURNAL
- Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
- (2015) Emma Loveman et al. BMC Pulmonary Medicine
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- How does comorbidity influence survival in idiopathic pulmonary fibrosis?
- (2014) Charlotte Hyldgaard et al. RESPIRATORY MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
- (2011) Paul W Noble et al. LANCET
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
- (2011) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
- (2010) Kenneth F Schulz et al. Trials
- Pirfenidone in idiopathic pulmonary fibrosis
- (2009) H. Taniguchi et al. EUROPEAN RESPIRATORY JOURNAL
- Sex differences in physiological progression of idiopathic pulmonary fibrosis
- (2008) M. K. Han et al. EUROPEAN RESPIRATORY JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started